<DOC>
	<DOCNO>NCT02688647</DOCNO>
	<brief_summary>This study conduct evaluate safety , tolerability , activity 400 mg KD025 once-daily ( QD ) compare standard care ( SOC ) male postmenopausal/surgically sterilize female subject IPF .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Activity KD025 Subjects With Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description>Thirty-six ( 36 ) male postmenopausal/surgically sterilize female subject IPF eligible , randomly enrol 2:1 ratio ( KD025 SOC ) one two treatment group . Subjects randomize Treatment Group 1 receive KD025 400 mg QD orally 24 week . Subjects randomize Treatment Group 2 receive SOC ( deem appropriate investigator ) . Subjects randomize SOC treat exactly subject KD025 undergo test similar fashion .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>Adult male postmenopausal/surgically sterilize female subject least 18 year age ( female , surgically sterilize [ ie , total hysterectomy , bilateral salpingooophorectomy ] ) Able provide write informed consent performance study specific procedure IPF diagnosis within 5 year study entry , proven accord American Thoracic Society/European Respiratory Society consensus conference criterion , surgical lung biopsy . In absence surgical lung biopsy , HRCT must consistent usual interstitial pneumonitis . Resting state SpO2 ≥ 88 % without supplemental oxygen , FVC % ≥ 50 % normal predict value , DLCO ≥ 30 % normal predict value baseline Men partner childbearing potential must willing use 2 medically acceptable method contraception trial 1 month last dose study drug . Effective birth control include ( ) intrauterine device ( IUD ) plus 1 barrier method ; ( b ) stable dos hormonal contraception least 3 month ( eg , oral , injectable , implant , transdermal ) plus 1 barrier method ; ( c ) 2 barrier method . Effective barrier method male female condom , diaphragm , spermicide ( creams gel contain chemical kill sperm ) ; ( ) vasectomy . Have adequate bone marrow function : 1 . ANC &gt; 1500/mm3 2 . Hemoglobin &gt; 9.0 g/L 3 . Platelets &gt; 100,000/mm3 Willing complete study measurement assessment compliance protocol Has either receive pirfenidone and/or nintedanib offer treatment ( last dose administer least 1 month expect start study drug dose ) . If either pirfenidone nintedanib treatment give , documentation patient offer treatment must document . Interstitial lung disease cause condition IPF Severe concomitant illness limit life expectancy ( &lt; 1 year ) Diffusing capacity lung carbon monoxide ( DLCO ) &lt; 30 % predict Residual volume ≥ 120 % predict Obstructive lung disease : FEV1/ FVC ratio &lt; 0.70 Documented sustain improvement subject 's IPF condition 12 month study entry without IPFspecific therapy Pulmonary upper respiratory tract infection within 4 week study entry Acute chronic impairment ( dyspnea ) limit ability comply study requirement ( eg , pulmonary function test ) Chronic heart failure New York Heart Association class III/IV know leave ventricular ejection fraction &lt; 25 % Moderate severe hepatic impairment ( ie , ChildPugh Class B C ) Estimated creatinine clearance &lt; 30 mL/min Aspartate aminotransferase ( AST ) and/or ALT &gt; 2.0 × upper limit normal ( ULN ) Hemoglobin &lt; 75 % low limit normal Systolic blood pressure &lt; 100 mmHg Men whose partner pregnant breastfeeding Current drug alcohol dependence Chronic treatment follow drug ( within 4 week study entry study ) 1 . Immunosuppressive cytotoxic drug include cyclophosphamide azathioprine 2 . Antifibrotic drug include pirfenidone , nintedanib , D penicillamine , colchicine , tumor necrosis factor α blocker , imatinib interferonγ 3 . Chronic use Nacetylcysteine prescribe IPF ( &gt; 600 mg/day ) 4 . Oral anticoagulant prescribe IPF Treatment endothelin receptor antagonist within 4 week study entry Systemic treatment within 4 week study entry cyclosporine A tacrolimus , everolimus , sirolimus ( calcineurin mammalian target rapamycin inhibitor ) Previous exposure KD025 know allergy/sensitivity KD025 ROCK2 inhibitor Planned treatment , treatment another investigational drug within 4 week study entry Subject take medication potential QTc prolongation ( see Appendix A ) Subject take drug sensitive substrate CYP enzymes Subject take inhibitor inducer CYP3A4 ( see Appendix B ) Subject consume herbal medication ( eg , St. John 's Wort ) grapefruit/grapefruit juice within 14 day prior Week 1 , Day 1 visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Pulmonary Fibrosis</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>Idiopathic Interstitial Pneumonias</keyword>
	<keyword>Lung Diseases</keyword>
</DOC>